Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care

Prim Care Diabetes. 2019 Dec;13(6):485-494. doi: 10.1016/j.pcd.2019.07.001. Epub 2019 Aug 7.

Abstract

Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes mellitus (T2DM). Furthermore, CKD confers a considerable increase in the risk of cardiovascular (CV) morbidity and mortality. In line with the need to improve knowledge in this field, this article aims to describe the renal endpoints used in the different cardiovascular outcome trials (CVOTs). The objective is to better know the renal variables used in the different CVOTs in order to optimize the implementation of advances in the prevention of progressive diabetic kidney disease in patients with T2DM in clinical practice.

Keywords: Diabetic kidney disease; Diabetic nephropathy; Major adverse renal event; Primary care; Renal endpoints; Renal outcome; Type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetic Nephropathies / complications
  • Diabetic Nephropathies / drug therapy*
  • Global Health
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Morbidity / trends
  • Primary Health Care / methods*
  • Risk Factors
  • Survival Rate / trends

Substances

  • Hypoglycemic Agents